The FDA has approved Eysuvis for the short-term treatment of dry eye disease signs and symptoms, according to a press release from Kala Pharmaceuticals.
Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%) is the first ocular corticosteroid approved by the FDA for the treatment of dry eye disease. Kala is planning to launch it in the U.S. by the end of the year.
The approval is based on results from four clinical trials that demonstrated significant improvement in signs and symptoms of dry eye disease. Eysuvis is approved for up to 2 (Read more...)
Uncategorized